Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

Articles

Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple Myeloma

June 19th 2023

Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

March 13th 2023

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Does Belantamab Have a Place in Multiple Myeloma Treatment?

March 13th 2023

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Preventing Infection in Patients with Multiple Myeloma During Treatment

March 13th 2023

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

March 6th 2023

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Targets in Multiple Myeloma: FcRH5

March 6th 2023

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Targets in Multiple Myeloma: GPRC5D

February 27th 2023

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Data Updates on Immunotherapy Combinations in Multiple Myeloma

February 27th 2023

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Retreatment with a BCMA-Targeting Bispecific for R/R MM

February 20th 2023

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

February 20th 2023

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

February 13th 2023

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

February 13th 2023

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Quadruplet Combination Therapies in Relapsed Multiple Myeloma

February 6th 2023

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

Strategies for Treatment of Multiple Myeloma at Late Relapse

February 6th 2023

The panel debates the options for treatment of late relapsed multiple myeloma.

Data Updates in the Treatment of Relapsed Multiple Myeloma

January 30th 2023

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Relapse in Multiple Myeloma: Biochemical and Chemical

January 30th 2023

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

January 23rd 2023

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Defining Frailty in Multiple Myeloma for Optimal Treatment

January 23rd 2023

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Unmet Needs in the Treatment of NDMM and R/R MM and Clinical Pearls for Community Oncologists

January 17th 2023

The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.

Treatment Options for MM at Early Relapse

January 17th 2023

Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.